您要查找的是不是：
- This is less common with acute myelogenous leukemia. 而这种情况在急粒患者中发生的比例更小。
- Objective To explore the expression and significance of WT1 gene in patients with acute myelogenous leukemia(AML). 目的探讨WT1基因在急性髓细胞白血病(AML)患者中的表达及其与临床治疗和预后的关系。
- At high power, the bone marrow of a patient with acute myelogenous leukemia is seen here. 在高倍镜下，见到的是急性髓母细胞白血病骨髓。
- Objective To approach curative effect of using DLI +IL-2 as immunobiotherapy after Mixed-HSCT in acute myelogenous leukemia. 目的探讨急性髓性白血病在经过混合造血干细胞移植(mixed-HSCT)后,应用供体淋巴细胞输注(DLI)+白介素-2(IL-2)作为后续免疫生物治疗措施的意义。
- Immuno-biotherapy with DLI +IL-2 after Mixed-HSCT in patients of acute myelogenous leukemia may be a method to increase DFS efficiently. Mixed-HSCT后应用DLI+IL-2,可能是有效提高长期生存率的免疫生物治疗措施之一。
- Objective To investigate the changes of serum VEGF and SE-CAD levels in patients with acute myelogenous leukemia after treatment. 目的探讨了急性髓系白血病患者治疗前后血清VEGF和SE-CAD水平的变化。
- Anthracycline drugs may also increase the risk of developing a secondary cancer, such as acute myelogenous leukemia or myelodysplastic syndromes. 蒽环类药物也会增加发生二次肿瘤的风险，如急性髓细胞白血病，或骨髓增生异常综合征。
- Procarbazine, nitrogen mustard, and ifosfamide, which can increase risk for myelodysplastic syndromes and acute myelogenous leukemia. 丙卡巴肼、氮芥和异环磷酰胺：可增加患骨髓增生异常综合症和急性粒细胞白血病的风险。
- At high power, the bone marrow of a patient with acute myelogenous leukemia is seen here. There is one lone megakaryocyte at the right center. 在高倍镜下,见到的是急性髓母细胞白血病骨髓。在右侧中心处有一个孤立巨核细胞。
- Heart muscle damage is usually related to the cumulative dosage of anthracyclines, many of which are used to treat acute myelogenous leukemia. 蒽环类药物多数用于治疗急性髓细胞白血病。
- Anthracycline drugs may also increase the risk for developing a secondary cancer, such as acute myelogenous leukemia or myelodysplastic syndrome. 蒽环类药物还可能增加继发性癌症（如急性粒细胞白血病或骨髓增生异常综合症）的发病风险。
- Cancer stem cells can not only be isolated from acute myelogenous leukemia, but also be proved in solid cancer-breast cancer. 肿瘤干细胞不仅能够从血液系统恶性肿瘤中分离，乳腺癌实体瘤干细胞的成功分离也证实了肿瘤干细胞的存在。
- Objective\ To observe the curative effect to acute myelogenous leukemia (AML) of the pirarubicin united Ara-C (TA) regimen. 目的观察吡柔比星联合化疗方案对急性髓细胞性白血病的疗效。
- Result DFS in 8 cases of patients with acute myelogenous leukemia received Mixed-HSCT and treated with DLI +IL-2 for 2-7 times were 62.5%. There were no GVHD. 经过1~5年观察;8例患者Mixed-HSCT后应用DLI+IL-2治疗的患者长期生存率为62.;5%25。
- Objective:To evaluate the antileukemic activity and side effects of topotecan-based induction therapy in patients with refractory and relapsed acute myelogenous leukemia(AML). 目的 :评价以拓扑替康为基础的联合诱导方案治疗难治及复发急性粒细胞白血病 (AML)的疗效及不良反应。
- In 70s, it had been confirmed that HHT had favorably therapeutic activity in patients with acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML). 我国在70年代将其用于急性非淋巴细胞白血病(AML)和慢性粒细胞白血病(CML)的治疗取得良好疗效。
- MethodAfter times of chemotherapy,8 cases of patients with acute myelogenous leukemia received Mixed-HSCT,then were treated with DLI +IL-2 for 2-7 times. 方法8例急性髓性白血病患者在完全缓解期实施了Mixed-HSCT,于造血恢复后,给予DLI+IL-2治疗2~7次,并随访观察临床疗效。
- Acute myelogenous leukemia (AML) is a cancer of the bone marrow that makes new blood cells and it develops as a result of DNA mutations that accumulate as a person grows older. 急性骨髓性白血病(AML)是造血系统骨髓瘤的一种，随着患者年龄的增长，这种肿瘤将逐渐发展累计导致基因的突变。
- Other examples of monoclonal antibodies being tested in clinical trials include:Bevacizumab for chronic myelogenous leukemia (CML) and acute myelogenous leukemia (AML). 正在进行临床测试的其他单克隆抗体的例子包括： 贝伐单抗，用于慢性和急性的髓细胞白血病。
- Objective To explore the suitable consolidation therapy strategy of the acute myelogenous leukemia (AML) after complete cytomorphological remission (CR). 摘要目的：探讨急性髓系白血病(AML)诱导缓解后的适宜强化治疗方案。
以上内容独家创作，受著作权保护，侵权必究
海词词典，十七年品牌
